

Supplementary Table S5. Multivariate and sex-adjusted (as confounder) Cox regression analysis by genotype for any cancer. Note: Significant polymorphism genotypes are in Bold. Abbreviations: HR: Hazards Ratio, CI: Confidence Interval, Ref: Reference genotype.

Polymorphism	Genotype (N)	Cancer affected (N)	HR (95% CI)	P-value	#P-value	*Adjusted HR (95% CI)	P-value	#P-value
HFE H63D rs1799945								
CC	277	134	Ref			Ref		
CG	56	26	0.96 (0.58-1.59)	0.870	0.982	1.03 (0.62-1.73)	0.900	0.983
CT	2	1	1.20 (0.15-9.61)	0.870	0.982	0.85 (0.11-6.78)	0.880	0.983
GG	2	1	0.36 (0.05-2.83)	0.330	0.600	0.27 (0.03-2.19)	0.220	0.513
CYP17 rs743572								
AA	68	35	Ref			Ref		
AG	156	81	1.53 (0.95-2.46)	0.080	0.342	1.56 (0.96-2.53)	0.070	0.267
GG	60	24	1.01 (0.56-1.82)	0.980	0.999	1.00 (0.55-1.80)	1.000	0.999
GT	23	13	1.83 (0.87-3.84)	0.110	0.346	2.01 (0.94-4.32)	0.072	0.267
AT	32	10	0.48 (0.21-1.09)	0.080	0.342	0.48 (0.21-1.08)	0.076	0.267
TT	1	0	0.00 (0.00-inf)	1.000	0.999	0.00 (0.00-inf)	1.000	0.999
hTERT rs2075786								
AA	108	48	Ref			Ref		
AG	161	86	1.20 (0.80-1.78)	0.380	0.634	1.21 (0.80-1.82)	0.360	0.631
GG	70	33	1.39 (0.85-2.29)	0.190	0.494	1.44 (0.87-2.37)	0.160	0.419
PPP2R2B rs10477307								
GG	129	70	Ref			Ref		
GA	166	72	0.73 (0.50-1.07)	0.110	0.345	0.71 (0.48-1.05)	0.088	0.279
AA	43	20	0.74 (0.40-1.36)	0.330	0.600	0.76 (0.41-1.40)	0.380	0.631
KIF20A rs10038448								
CC	213	99	Ref			Ref		
GC	112	57	0.85 (0.48-1.49)	0.560	0.737	0.92 (0.51-1.65)	0.780	0.959
GG	15	7	1.09 (0.28-4.22)	0.900	0.989	0.95 (0.25-3.53)	0.940	0.993
TGFB1/CCDC 97 rs12980942								
GG	289	145	Ref			Ref		
GA	46	15	0.60 (0.33-1.09)	0.094	0.346	0.57 (0.31-1.05)	0.071	0.267
AA	4	3	2.92(0.72-11.77)	0.130	0.376	2.22 (0.56-8.91)	0.260	0.530
XRCC5 rs1051685								
AA	176	90	Ref			Ref		

AG	132	58	0.58 (0.40-0.84)	0.005	0.157	0.62 (0.42-0.92)	0.017	0.267
GG	32	15	0.79 (0.42-1.48)	0.460	0.676	0.90 (0.48-1.68)	0.730	0.947
TNF rs3093662								
AA	273	136	Ref			Ref		
AG	62	26	1.35 (0.82-2.23)	0.240	0.522	1.17 (0.70-1.95)	0.550	0.797
GG	4	1	0.41 (0.05-3.19)	0.390	0.634	0.36 (0.05-2.78)	0.330	0.630
BCL2 rs1531697								
TT	168	76	Ref			Ref		
TA	139	72	1.10 (0.76-1.59)	0.610	0.763	1.10 (0.76-1.59)	0.620	0.830
AA	31	14	0.53 (0.26-1.07)	0.078	0.342	0.44 (0.22-0.90)	0.024	0.267
CHFR rs11610954								
CC	291	137	Ref			Ref		
CT	43	23	1.76 (1.04-2.99)	0.037	0.333	1.73 (1.00-2.98)	0.048	0.267
TT	6	3	1.67 (0.49-5.65)	0.410	0.639	1.53 (0.46-5.18)	0.490	0.780
CDC25C rs6874130								
GG	104	48	Ref			Ref		
GC	183	88	1.02 (0.65-1.59)	0.940	0.998	0.94 (0.60-1.47)	0.790	0.959
CC	53	27	0.86 (0.44-1.67)	0.650	0.787	0.84 (0.43-1.63)	0.600	0.830
ATM rs1800057								
CC	330	155	Ref			Ref		
CG	10	8	1.33 (0.55-3.26)	0.530	0.716	1.08 (0.44-2.64)	0.870	0.983
CYP1A1 Msp1 rs4646903								
AA	230	112	Ref			Ref		
AG	85	40	0.64 (0.42-0.98)	0.039	0.333	0.64 (0.42-0.97)	0.036	0.267
GG	19	10	1.47 (0.67-3.22)	0.340	0.600	1.29 (0.58-2.89)	0.530	0.797
TTC28 rs9608696								
TT	329	156	-	-		-	-	
GG	0	0						
CDC25C rs3734166								
GG	185	77	Ref			Ref		
GA	133	76	1.69 (0.99-2.87)	0.053	0.342	1.70 (0.99-2.92)	0.056	0.267
AA	20	8	1.59 (0.42-6.01)	0.490	0.701	2.20 (0.60-8.07)	0.230	0.513
GSTM1 + (Present)	275	129	Ref			Ref		
- (Null)	55	30	1.69 (1.03-2.75)	0.036	0.522	1.52 (0.93-2.50)	0.096	0.279

GSTT1								
+ (Present)	256	126	Ref			Ref		
- (Null)	74	33	0.76 (0.49-1.20)	0.250	0.494	0.75 (0.47-1.18)	0.210	0.513
*Adjusted for gender #Corrected for multiple testing using the Benjamin-Hochberg method.								